FR17C1062I2 - Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques - Google Patents
Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiquesInfo
- Publication number
- FR17C1062I2 FR17C1062I2 FR17C1062C FR17C1062C FR17C1062I2 FR 17C1062 I2 FR17C1062 I2 FR 17C1062I2 FR 17C1062 C FR17C1062 C FR 17C1062C FR 17C1062 C FR17C1062 C FR 17C1062C FR 17C1062 I2 FR17C1062 I2 FR 17C1062I2
- Authority
- FR
- France
- Prior art keywords
- therapeutic
- specific antibodies
- diagnostic uses
- disclosed
- human specific
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
- G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- General Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0210121.0A GB0210121D0 (en) | 2002-05-02 | 2002-05-02 | Biological products |
PCT/GB2003/001934 WO2003093320A2 (fr) | 2002-05-02 | 2003-05-02 | Produits biologiques |
Publications (2)
Publication Number | Publication Date |
---|---|
FR17C1062I1 FR17C1062I1 (fr) | 2018-02-16 |
FR17C1062I2 true FR17C1062I2 (fr) | 2020-05-29 |
Family
ID=9935990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR17C1062C Active FR17C1062I2 (fr) | 2002-05-02 | 2017-12-21 | Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques |
Country Status (35)
Country | Link |
---|---|
US (8) | US7355011B2 (fr) |
EP (1) | EP1504035B9 (fr) |
JP (3) | JP4486494B2 (fr) |
KR (3) | KR101238970B1 (fr) |
CN (3) | CN103172742B (fr) |
AT (1) | ATE462729T3 (fr) |
AU (1) | AU2003223007C1 (fr) |
BE (1) | BE2017C068I2 (fr) |
CA (1) | CA2484420C (fr) |
CO (1) | CO5631451A2 (fr) |
CY (3) | CY1110134T1 (fr) |
DE (1) | DE60331910D1 (fr) |
DK (1) | DK1504035T6 (fr) |
EC (1) | ECSP045470A (fr) |
ES (1) | ES2341708T7 (fr) |
FR (1) | FR17C1062I2 (fr) |
GB (1) | GB0210121D0 (fr) |
HK (2) | HK1071762A1 (fr) |
HU (2) | HUS1700055I1 (fr) |
IL (1) | IL164923A (fr) |
LT (2) | LTC1504035I2 (fr) |
LU (2) | LUC00058I2 (fr) |
MX (1) | MXPA04010787A (fr) |
NL (1) | NL300920I2 (fr) |
NO (1) | NO336201B1 (fr) |
NZ (1) | NZ536757A (fr) |
PL (1) | PL218433B1 (fr) |
PT (1) | PT1504035E (fr) |
RU (1) | RU2342401C2 (fr) |
SG (1) | SG161744A1 (fr) |
SI (1) | SI1504035T1 (fr) |
TW (1) | TWI324161B (fr) |
UA (1) | UA92580C2 (fr) |
WO (1) | WO2003093320A2 (fr) |
ZA (1) | ZA200408851B (fr) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1448584B1 (fr) | 2001-09-26 | 2010-05-19 | The Government of the United States of America as represented by The Secretary of Health and Human Services | Anticorps anti-cd22 mutes a forte affinite pour les cellules leucemiques exprimant des cd22 |
US20110045005A1 (en) | 2001-10-19 | 2011-02-24 | Craig Crowley | Compositions and methods for the treatment of tumor of hematopoietic origin |
CA2476776A1 (fr) | 2002-02-21 | 2003-09-04 | Duke University | Reactifs et methodes therapeutiques de maladies auto-immunes |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
AR052774A1 (es) * | 2004-10-08 | 2007-04-04 | Wyeth Corp | Inmunoterapia para trastornos autoinmunes |
EP1909831A4 (fr) | 2005-06-14 | 2013-02-20 | Amgen Inc | Préparations de protéines à tamponnage spontané |
MY149159A (en) | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
EP2639242A3 (fr) * | 2006-03-06 | 2013-10-16 | MedImmune, Inc. | Anticorps humanisés dirigés contre l'antigène CD22 et leur utilisation dans le traitement de l'oncologie, des transplantations et les maladies auto-immunes |
US8389688B2 (en) | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
CA2652945C (fr) * | 2006-05-30 | 2015-06-02 | Genentech, Inc. | Anticorps et immuno-conjugues, et leurs utilisations |
CN101626782B (zh) | 2006-12-01 | 2013-03-27 | 梅达雷克斯公司 | 结合cd22的人抗体及其用途 |
US8591889B2 (en) | 2008-04-04 | 2013-11-26 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Human monoclonal antibodies specific for CD22 |
WO2010075249A2 (fr) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | Méthode de traitement de la polyarthrite rhumatoïde avec des antagonistes de cellules b |
WO2010096394A2 (fr) | 2009-02-17 | 2010-08-26 | Redwood Biosciences, Inc. | Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation |
MX353186B (es) | 2009-09-03 | 2018-01-05 | Genentech Inc | Metodos para el tratamiento, diagnosis y monitoreo de artritis reumatoide. |
JP6162606B2 (ja) | 2011-01-14 | 2017-07-12 | レッドウッド バイオサイエンス, インコーポレイテッド | アルデヒド−タグ付き免疫グロブリンポリペプチド及びその使用方法 |
EP2680884B1 (fr) | 2011-02-28 | 2018-01-17 | F. Hoffmann-La Roche AG | Marqueurs biologiques et procédés de prédiction de réponse à des antagonistes de lymphocytes b |
JP2015516984A (ja) * | 2012-04-26 | 2015-06-18 | バイオアトラ、エルエルシー | 抗cd22抗体 |
WO2014008404A1 (fr) | 2012-07-03 | 2014-01-09 | Washington University | Anticorps dirigés contre tau |
CN104582717B (zh) | 2012-07-19 | 2018-03-13 | 雷德伍德生物科技股份有限公司 | 对cd22有特异性的抗体及其使用方法 |
RU2658485C2 (ru) * | 2012-10-24 | 2018-06-21 | Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез | Химерные антигенные рецепторы м971 |
CN103214578B (zh) * | 2013-05-10 | 2014-05-28 | 北京东方百泰生物科技有限公司 | 一种新型的人源化抗cd22抗体 |
TW201605480A (zh) | 2013-11-04 | 2016-02-16 | 輝瑞大藥廠 | 抗efna4抗體-藥物結合物 |
GB201409558D0 (en) | 2014-05-29 | 2014-07-16 | Ucb Biopharma Sprl | Method |
TW202136296A (zh) | 2014-06-27 | 2021-10-01 | 美商C2N醫療診斷有限責任公司 | 人類化抗-tau抗體 |
GB201412658D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
GB201412659D0 (en) | 2014-07-16 | 2014-08-27 | Ucb Biopharma Sprl | Molecules |
KR20170134642A (ko) * | 2015-04-08 | 2017-12-06 | 노파르티스 아게 | Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법 |
GB201601075D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies molecules |
GB201601077D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibody molecule |
GB201601073D0 (en) | 2016-01-20 | 2016-03-02 | Ucb Biopharma Sprl | Antibodies |
GB201521382D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521389D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Method |
GB201521383D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl And Ucb Celltech | Method |
GB201521393D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
GB201521391D0 (en) | 2015-12-03 | 2016-01-20 | Ucb Biopharma Sprl | Antibodies |
JP2019515677A (ja) | 2016-04-26 | 2019-06-13 | アール.ピー.シェーラー テクノロジーズ エルエルシー | 抗体複合体ならびにそれを作製および使用する方法 |
GB201610512D0 (en) * | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
US20180110856A1 (en) | 2016-10-21 | 2018-04-26 | Amgen Inc. | Pharmaceutical Formulations and Methods of Making the Same |
MX2020010227A (es) | 2018-03-30 | 2021-02-17 | Eureka Therapeutics Inc | Construcciones dirigidas a cd22 y usos de las mismas. |
JP2023521635A (ja) * | 2020-04-02 | 2023-05-25 | ナンチン イアソ バイオセラピューティクス カンパニー,リミティド | 全ヒト化抗ヒトcd22のキメラ抗原受容体及びその応用 |
CN114106177B (zh) * | 2020-08-27 | 2024-04-09 | 深圳市菲鹏生物治疗股份有限公司 | Cd22抗体及其应用 |
WO2022262783A1 (fr) * | 2021-06-16 | 2022-12-22 | 西安宇繁生物科技有限责任公司 | Anticorps entièrement humain anti-cd22 ou fragment de liaison à l'antigène de celui-ci, son procédé de préparation et son utilisation |
AU2022333837A1 (en) * | 2021-08-27 | 2024-03-14 | Peptron, Inc. | Novel anti-muc1 antibody and use thereof |
US20240166705A1 (en) | 2022-11-07 | 2024-05-23 | Xencor, Inc. | Il18-fc fusion proteins |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3957362A (en) * | 1972-10-02 | 1976-05-18 | Corneal Sciences, Inc. | Hydrogels and articles made therefrom |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) * | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5134075A (en) * | 1989-02-17 | 1992-07-28 | Oncogen Limited Partnership | Monoclonal antibody to novel antigen associated with human tumors |
GB8928874D0 (en) * | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
ES2264239T3 (es) * | 1990-06-27 | 2006-12-16 | Princeton University | Complejo de proteinas p53/p90'. |
HU219537B (hu) * | 1991-03-06 | 2001-05-28 | Merck Patent Gmbh. | Humanizált és kiméra monoklonális antitestek, azokat tartalmazó gyógyászati készítmények, az antitesteket kódoló szekvenciát tartalmazó expressziós vektorok, valamint eljárás az antitestek előállítására |
US5714350A (en) * | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5686072A (en) | 1992-06-17 | 1997-11-11 | Board Of Regents, The University Of Texas | Epitope-specific monoclonal antibodies and immunotoxins and uses thereof |
US5714340A (en) * | 1992-12-22 | 1998-02-03 | Johnson & Johnson Clinical Diagnostics, Inc. | Immunoassay elements having a receptor zone |
US6180377B1 (en) * | 1993-06-16 | 2001-01-30 | Celltech Therapeutics Limited | Humanized antibodies |
US5474995A (en) | 1993-06-24 | 1995-12-12 | Merck Frosst Canada, Inc. | Phenyl heterocycles as cox-2 inhibitors |
US5436265A (en) * | 1993-11-12 | 1995-07-25 | Merck Frosst Canada, Inc. | 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents |
DK1759709T3 (da) | 1994-01-25 | 2013-06-10 | Elan Pharm Inc | Humaniserede antistoffer mod leukocytadhæsionsmolekyle VLA-4 |
ATE201445T1 (de) | 1994-08-12 | 2001-06-15 | Myriad Genetics Inc | Mutationen des mit 17q verbundenen ovarial- und brustkrebs empfindlichkeitsgens |
AU3272695A (en) * | 1994-08-12 | 1996-03-07 | Immunomedics Inc. | Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US7147851B1 (en) * | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
US20020141990A1 (en) * | 1996-11-01 | 2002-10-03 | Smithkline Beecham Corporation | Anti-RSV human monoclonal antibodies |
EP0977590A4 (fr) * | 1996-11-01 | 2001-03-14 | Smithkline Beecham Corp | Anticorps monoclonaux humains |
US5980898A (en) | 1996-11-14 | 1999-11-09 | The United States Of America As Represented By The U.S. Army Medical Research & Material Command | Adjuvant for transcutaneous immunization |
AU740904B2 (en) * | 1997-03-20 | 2001-11-15 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
US6183744B1 (en) | 1997-03-24 | 2001-02-06 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
ES2190087T3 (es) | 1997-06-13 | 2003-07-16 | Genentech Inc | Formulacion estabilizada de un anticuerpo. |
AT408613B (de) * | 1998-06-17 | 2002-01-25 | Immuno Ag | Pharmazeutisches faktor vii-präparat |
KR100345463B1 (ko) * | 1998-11-19 | 2003-01-08 | 주)녹십자 | B형간염바이러스의표면항원프리-s1에대한인간화항체및이의제조방법 |
EP1194167B1 (fr) * | 1999-06-09 | 2009-08-19 | Immunomedics, Inc. | Immunotherapie de troubles auto-immuns a l'aide d'anticorps ciblant les cellules b |
DK1232392T3 (da) * | 1999-10-12 | 2003-07-28 | Connex Ges Zur Optimierung Von | Forbedret fremgangsmåde til påvisning af syreresistente bakterier af slægten Helicobacter i afføring |
WO2002004021A1 (fr) * | 2000-07-12 | 2002-01-17 | Idec Pharmaceuticals Corporation | Traitement de malignites des cellules b au moyen d'une combinaison d'anticorps a action depletive sur les cellules b et des applications relatives a l'anticorps de modulation immunitaire |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
GB0013810D0 (en) * | 2000-06-06 | 2000-07-26 | Celltech Chiroscience Ltd | Biological products |
CN1205479C (zh) * | 2000-10-31 | 2005-06-08 | 杨梦甦 | 免疫学诊断蛋白芯片制备方法 |
PL224001B1 (pl) | 2002-05-02 | 2016-11-30 | Wyeth Corp | Sposób wytwarzania stabilnej liofilizowanej kompozycji obejmującej monomeryczne koniugaty pochodna kalicheamycyny/przeciwciało anty-CD22, kompozycja otrzymana tym sposobem oraz jej zastosowanie |
GB0210121D0 (en) * | 2002-05-02 | 2002-06-12 | Celltech R&D Ltd | Biological products |
US8389688B2 (en) * | 2006-03-06 | 2013-03-05 | Aeres Biomedical, Ltd. | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
-
2002
- 2002-05-02 GB GBGB0210121.0A patent/GB0210121D0/en not_active Ceased
-
2003
- 2003-05-02 EP EP03718974.3A patent/EP1504035B9/fr not_active Expired - Lifetime
- 2003-05-02 US US10/428,408 patent/US7355011B2/en active Active
- 2003-05-02 KR KR1020107027192A patent/KR101238970B1/ko active IP Right Grant
- 2003-05-02 UA UA20041209866A patent/UA92580C2/ru unknown
- 2003-05-02 MX MXPA04010787A patent/MXPA04010787A/es active IP Right Grant
- 2003-05-02 AT AT03718974T patent/ATE462729T3/de unknown
- 2003-05-02 ES ES03718974.3T patent/ES2341708T7/es active Active
- 2003-05-02 CN CN201310021287.1A patent/CN103172742B/zh not_active Expired - Lifetime
- 2003-05-02 CN CN2007100852904A patent/CN101134779B/zh not_active Expired - Lifetime
- 2003-05-02 AU AU2003223007A patent/AU2003223007C1/en active Active
- 2003-05-02 TW TW092112182A patent/TWI324161B/zh not_active IP Right Cessation
- 2003-05-02 RU RU2004135103/13A patent/RU2342401C2/ru active
- 2003-05-02 CN CNB038150433A patent/CN100384878C/zh not_active Expired - Lifetime
- 2003-05-02 PL PL373277A patent/PL218433B1/pl unknown
- 2003-05-02 SI SI200331804T patent/SI1504035T1/sl unknown
- 2003-05-02 DE DE60331910T patent/DE60331910D1/de not_active Expired - Lifetime
- 2003-05-02 PT PT03718974T patent/PT1504035E/pt unknown
- 2003-05-02 DK DK03718974.3T patent/DK1504035T6/en active
- 2003-05-02 KR KR1020047017615A patent/KR101156796B1/ko active IP Right Grant
- 2003-05-02 SG SG200608406-5A patent/SG161744A1/en unknown
- 2003-05-02 WO PCT/GB2003/001934 patent/WO2003093320A2/fr active Application Filing
- 2003-05-02 CA CA2484420A patent/CA2484420C/fr not_active Expired - Lifetime
- 2003-05-02 JP JP2004501459A patent/JP4486494B2/ja not_active Expired - Lifetime
- 2003-05-02 KR KR1020127025129A patent/KR101386376B1/ko active IP Right Grant
- 2003-05-02 NZ NZ536757A patent/NZ536757A/en not_active IP Right Cessation
-
2004
- 2004-10-28 IL IL164923A patent/IL164923A/en active IP Right Grant
- 2004-11-02 ZA ZA2004/08851A patent/ZA200408851B/en unknown
- 2004-11-02 NO NO20044742A patent/NO336201B1/no not_active IP Right Cessation
- 2004-11-30 CO CO04120665A patent/CO5631451A2/es active IP Right Grant
- 2004-12-02 EC EC2004005470A patent/ECSP045470A/es unknown
-
2005
- 2005-05-27 HK HK05104462.6A patent/HK1071762A1/xx not_active IP Right Cessation
-
2006
- 2006-09-11 US US11/519,585 patent/US20070059307A1/en not_active Abandoned
-
2008
- 2008-09-23 US US12/235,724 patent/US7919606B2/en not_active Expired - Lifetime
-
2009
- 2009-09-07 JP JP2009205660A patent/JP5377173B2/ja not_active Expired - Lifetime
-
2010
- 2010-06-03 CY CY20101100492T patent/CY1110134T1/el unknown
-
2011
- 2011-03-16 US US13/049,087 patent/US8895714B2/en active Active
-
2012
- 2012-07-13 US US13/548,542 patent/US20120302739A1/en not_active Abandoned
-
2013
- 2013-07-04 JP JP2013140245A patent/JP5920934B2/ja not_active Expired - Lifetime
- 2013-12-12 HK HK13113804.4A patent/HK1186479A1/zh not_active IP Right Cessation
-
2016
- 2016-03-14 US US15/069,078 patent/US20160326247A1/en not_active Abandoned
-
2017
- 2017-01-27 US US15/417,973 patent/US20170145114A1/en not_active Abandoned
- 2017-12-20 CY CY2017046C patent/CY2017046I2/el unknown
- 2017-12-21 CY CY2017045C patent/CY2017045I2/el unknown
- 2017-12-21 BE BE2017C068C patent/BE2017C068I2/nl unknown
- 2017-12-21 NL NL300920C patent/NL300920I2/nl unknown
- 2017-12-21 LT LTPA2017044C patent/LTC1504035I2/lt unknown
- 2017-12-21 LT LTPA2017043C patent/LTPA2017043I1/lt unknown
- 2017-12-21 FR FR17C1062C patent/FR17C1062I2/fr active Active
- 2017-12-21 LU LU00058C patent/LUC00058I2/en unknown
- 2017-12-21 LU LU00057C patent/LUC00057I2/en unknown
- 2017-12-22 HU HUS1700055C patent/HUS1700055I1/hu unknown
- 2017-12-22 HU HUS1700056C patent/HUS1700056I1/hu unknown
-
2021
- 2021-01-19 US US17/151,911 patent/US20210371547A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR17C1062I2 (fr) | Anticorps specifiques a l' humain cd22 et leurs utilisation therapeutiques et diagnostiques | |
MY136603A (en) | Biological products | |
DE60237778D1 (de) | Antikörper gegen kdr, deren herstellung und verwendungen | |
DE69922261D1 (de) | Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten | |
FR12C0004I2 (fr) | Anticorps contre l'antigene ctla-4 humain et utilisation |